It is currently unclear whether the addition of chemotherapy to standard radiation therapy improves clinical outcome in patients with locoregionally advanced nasopharyngeal cancer. A meta-analysis was performed to evaluate the impact of integrating chemotherapy with external beam radiation therapy in this clinical setting. Using previously described methods, a protocol was developed outlining a meta-analysis examining the influence of chemoradiation versus radiation alone (control arm) in locoregionally advanced nasopharyngeal carcinoma. The outcomes of interest were disease-free/progression-free and overall survival. Literature search techniques, study inclusion criteria, and statistical procedures were prospectively defined. Data from all available randomized controlled trials was pooled using a fixed effects model (Peto). Results were expressed as summary relative risks. Statistical tests for heterogeneity were performed. If statistical heterogeneity was demonstrated, sensitivity analyses were performed to evaluate possible sources of heterogeneity across the included studies. The literature search identified six randomized controlled trials enrolling more than 1,500 patients. All trials compared standard radical external beam radiation therapy (control arm) with radiation plus chemotherapy delivered either adjuvantly, neoadjuvantly, or concurrently with radiation. Pooling all six studies using disease-free/progression-free survival as the endpoint demonstrated that the addition of chemotherapy to radiation therapy increased disease-free/progression-free survival by 37% at 2 years, 40% at 3 years, and 34% at 4 years after treatment. Likewise, the summary relative risk for overall survival at 2 years after treatment with the addition of chemotherapy to the treatment regimen was 0.80 (0.63-1.02), reflecting a 20% increase in 2-year survival. This finding was marginally non-statistically significant. Three-and 4-year survival was increased by 19% and 21%, respectively, with the data for 4-year survival being statistically significant. The addition of chemotherapy to standard radical radiation therapy for locoregionally advanced nasopharyngeal cancer increases both disease-free/progression-free and overall survival by 19 to 40% at 2 to 4 years after treatment, depending on the endpoint of interest. Future trials are needed to confirm these results and determine the most effective regimen for integrating chemotherapy with radiation therapy in this setting.
It is currently unclear whether the addition of chemotherapy to standard radiation therapy improves clinical outcome in patients with locoregionally advanced nasopharyngeal cancer. A meta-analysis was performed to evaluate the impact of integrating chemotherapy with external beam radiation therapy in this clinical setting. Using previously described methods, a protocol was developed outlining a meta-analysis examining the influence of chemoradiation versus radiation alone (control arm) in locoregionally advanced nasopharyngeal carcinoma. The outcomes of interest were disease-free/progression-free and overall survival. Literature search techniques, study inclusion criteria, and statistical procedures were prospectively defined. Data from all available randomized controlled trials was pooled using a fixed effects model (Peto). Results were expressed as summary relative risks. Statistical tests for heterogeneity were performed. If statistical heterogeneity was demonstrated, sensitivity analyses were performed to evaluate possible sources of heterogeneity across the included studies. The literature search identified six randomized controlled trials enrolling more than 1,500 patients. All trials compared standard radical external beam radiation therapy (control arm) with radiation plus chemotherapy delivered either adjuvantly, neoadjuvantly, or concurrently with radiation. Pooling all six studies using disease-free/progression-free survival as the endpoint demonstrated that the addition of chemotherapy to radiation therapy increased disease-free/progression-free survival by 37% at 2 years, 40% at 3 years, and 34% at 4 years after treatment. Likewise, the summary relative risk for overall survival at 2 years after treatment with the addition of chemotherapy to the treatment regimen was 0.80 (0.63-1.02), reflecting a 20% increase in 2-year survival. This finding was marginally non-statistically significant. Three-and 4-year survival was increased by 19% and 21%, respectively, with the data for 4-year survival being statistically significant. The addition of chemotherapy to standard radical radiation therapy for locoregionally advanced nasopharyngeal cancer increases both disease-free/progression-free and overall survival by 19 to 40% at 2 to 4 years after treatment, depending on the endpoint of interest. Future trials are needed to confirm these results and determine the most effective regimen for integrating chemotherapy with radiation therapy in this setting. Nasopharyngeal carcinoma (NPC) is a relatively rare tumor in the West. The incidence is highest among populations in Southern China and Southeast Asia, 1 with age-adjusted incidence rates of approximately 29 cases per 100,000. 2 Epidemiologic studies suggest multiple possible causes for this disease including viruses (i.e., Epstein-Barr virus), genetic predisposition, and dietary factors (e.g., salted fish). 3 No association between NPC and alcohol or tobacco has been demonstrated.
Most patients with NPC seek treatment with locally advanced disease, that is, involvement of cervical lymph nodes. Upwards of 90% of patients present in this manner, with bilateral neck involvement occurring in approximately 50% of cases. Because of this, radiation therapy has become the standard approach for the majority of patients. Surgery plays a limited role in the treatment of the primary tumor, although it is an important modality in the management of neck disease that is persistent or recurrent after radiation therapy.
Although radiation is effective in the management of patients with early-stage lesions, control of locoregionally advanced NPC remains poor. Five-year survival ranges from approximately 10% to 40%, 4 with high rates of both local and distant failure. In an attempt to improve clinical outcomes, chemotherapy has been used neoadjuvantly, concomitantly with radiation and after radical radiation. 4 Unfortunately, the majority of trials fail to show any significant improvement in disease-free or overall survival. 4 Nonetheless, most available studies enrolled small numbers of patients, limiting the statistical power to detect a possible beneficial effect of chemotherapy. This article presents the results of a metaanalysis that pools data from all randomized trials comparing chemoradiation with radiation therapy alone among patients with locoregionally advanced NPC. The pooled analysis of more than 1,500 patients should provide a clearer understanding of the impact of combined chemoradiation on the natural history of this disease.
MATERIALS AND METHODS
The methods used in the design and execution of this meta-analysis have been previously described. 5 Briefly, a prospective study protocol was developed outlining a meta-analysis to determine the impact of combined chemoradiation on the natural history of locoregionally advanced NPC versus radiation therapy alone. The outcomes of interest were diseasefree and overall survival at 2, 3, and 4 years after treatment. Eligibility criteria for study inclusion were determined prospectively, as were the data to be extracted from each published report. A plan for statistical analysis was also outlined in the study protocol.
A data extraction form was developed for recording relevant information from each included study. Two researchers performed data extraction, with differences in extraction forms resolved by consensus. Additional data collected but not specified as inclusion criteria included: study sample size, type of chemotherapy used, drug schedule and radiation therapy schedule, and technique.
Literature Search
Information retrieval was performed by previously described methods. 5 A MEDLARS search was conducted covering the years 1966 to 2001 inclusively. The MeSH term "nasopharyngeal neoplasms" was exploded, and all comparative trials were identified by reading the individual abstracts. CancerLit and the CD-ROM version of Current Contents were also searched. The Cochrane Collaborative Register of Trials database was also used. Because computer searches alone fail to yield all relevant literature, the electronic database searches were supplemented by manual searching of bibliographies of all retrieved papers as well as searches of textbooks. Published abstracts were not included in the literature search. If a series of papers was published, all data were retrieved from the most recent report. Abstracts were obtained from any reference that appeared relevant to the search. All languages were eligible for inclusion.
A physician investigator screened initial citations (in the form of abstracts) to exclude those that did not meet protocol inclusion criteria. Nonrandomized trials and studies using biologic or other noncytotoxic therapy were excluded. Copies of full articles for the remaining citations were obtained and screened using the following eligibility criteria: 1) published randomized controlled trials enrolling adult patients comparing combined chemoradiation (either neoadjuvant, concomitant, or after radiation therapy) to radiation therapy alone in locoregionally advanced NPC (control arm); 2) randomized controlled trials enrolling patients with recurrent disease were eligible only if patients with recurrent disease were analyzed separately; 3) acceptable tumor stages included stages III or IV without distant metastases; and 4) studies must have a minimum of 2-year follow-up.
Statistical Methods
The meta-analytic procedures used were those described by Peto et al. 6 This method is a modification of the Mantel-Haenszel method and is based on a fixed-effects model. Study data are summarized in 2 ϫ 2 matrices and a summary odds ratio (ORp) and its 95% CI is calculated. The endpoints of interest (event) are disease-free and overall survival at 2, 3, and 4 years after treatment. The expected number of events in the "experimental" arm (chemo ϩ radiation) of each study is calculated, and an estimate of the variance of the observed minus expected number of events in each study was then determined as well as the variance across all studies. The natural logarithm of the ORp is then estimated by dividing the sum of observed minus expected number of events by the sum of the variances. In the present study, an ORp greater than 1 signifies better outcomes with radiation therapy alone versus combined chemoradiation and is explained in the text below.
Before estimation of a summary odds ratio, a statistical test for homogeneity was performed (Q). This procedure tests the hypothesis that the effect sizes are equal in all the studies. 7 If Q exceeds the upper tail critical value of chi-square (p Ͻ 0.05) at k Ϫ 1 degrees of freedom (where k equals the number of studies analyzed), the observed variance in study effect size is significantly greater than what would be expected by chance if all studies shared a common population effect size. If the hypothesis that the studies are homogenous is rejected, the studies are not measuring an effect of the same size, and calculation of a pooled estimate of effect may be of questionable validity. In this setting, sensitivity analyses are performed to evaluate possible sources of heterogeneity.
RESULTS
The literature search yielded 44 citations for initial review. Of these, six appeared to meet protocol specified inclusion criteria, [7] [8] [9] [10] [11] [12] [13] and copies of full papers were obtained and reviewed. The article by Dosen et al. 10 was found to be a duplicate publication of the VUMCA trial. 11 Therefore, only the latter article was included in the meta-analysis. Table 1 provides an overview of all six included reports.
Overall, a total of 1,582 patients were available for analysis. All trials except that of Al-Sarraf et al. 7 used adjuvant or neoadjuvant chemotherapy. Al-Sarraf et al. used concurrent cisplatin followed by post-radiation therapy cisplatin and 5-fluorouracil. Rossi et al. 12 were the only group that did not use a cisplatin-based chemotherapy regimen. These investigators used a combination of vincristine, cyclophosphamide and doxorubicin. An additional issue with the Rossi et al. report is the large number of initially enrolled patients not randomized, i.e., 35%. Twelve percent of patients randomized to the chemotherapy arm did not receive chemotherapy. An additional 9% did not receive the planned six cycles for reasons other than relapse or toxicity (see ref. 12) .
Initially, all six trials were combined in a meta-analysis using 2-year disease-free survival as the endpoint of interest. Table 2 presents the individual study odds ratios and 95% CI for this analysis. Combining these six studies yielded a summary odds ratio of 0.63 (95% CI ϭ 0.52-0.78), which indicates a 37% increase in 2-year disease-free survival associated with combined chemoradiation versus radiation alone. An analysis for heterogeneity gave a value of Q of 25.5. With five degrees of freedom, this demonstrated the presence of substantial heterogeneity (p Ͻ 0.005), i.e., the studies are not measuring an effect of similar size across all trials. This brings into question the validity of pooling the studies to derive a summary estimate of effect. Therefore, reasons for the demonstrated heterogeneity were sought via sensitivity analyses.
Examining Table 2 shows that the individual study odds ratio for the Al-Sarraf report 8 is 0.16 (0.08 -0.31). The positive effect on survival for concurrent chemoradiation in this report is substantially greater than that seen in any other included trial. It should be noted that these investigators used concurrent cisplatinum and radiation versus neoadjuvant chemotherapy, which was used in all other trials. This finding suggests that superiority of concurrent chemoradiation versus other schedules may account for the statistical heterogeneity. One additional caveat that must be considered is that Al-Sarraf et al. 8 
contained 20% to 30% of patients with
World Health Organization grade I tumors (Table 3) . Because grade I tumors are considered to have a somewhat better prognosis that grades II-III, histology could potentially bias study results. To address these issues, a sensitivity analysis was performed by dropping reference 8 from the meta-analysis and recalculating ORp. This yielded a somewhat attenuated ORp of 0.73 with a 95% CI of 0.59 to 0.91, a statistically significant result despite the omission of Al-Sarraf from the analysis. The Q associated with this latter meta-analysis was 6.94. With 4 degrees of freedom, this showed a lack of statistical heterogeneity (p ϭ 0.14). This demonstrates that the initial heterogeneity is caused by the highly positive results of Al-Sarraf et al. 8 indicating that concurrent chemoradiation may be superior to neoadjuvant treatment schemes. The inclusion of some World Health Organization grade I tumors in reference 8 did not appear to have a major impact on study outcome, because when the ORp was recalculated without inclusion of these data, 100% Undifferentiated or poorly differentiated VUMCA 11 All WHO II-III Rossi 12 Approximately 70% undifferentiated with the remainder classified as squamous cell Ma 13 97% WHO II-III WHO, World Health Organization.
the outcome remained statistically significant favoring combined chemoradiation.
With the source of heterogeneity identified, data from the six trials were pooled using 3-and 4-year diseasefree/progression-free survival as the endpoints of interest. Figure 1 shows the results of the pooled analysis for 3-year disease-free/progression-free survival. The summary odds ratio was 0.60 (0.49 -0.73), a statistically significant result reflecting a 40% increase in 3-year disease-free/progression-free survival among patients treated with chemoradiation versus radiation alone. Even if reference 8 is excluded from this analysis, the ORp is only slightly attenuated at 0.69 (0.56 -0.85). Likewise, using 4-year disease-free survival as the endpoint of interest yielded an ORp of 0.66 (0.54 -0.80), also a statistically significant result. Overall, the addition of chemotherapy to radiation improved disease-free/progression-free survival by approximately 35% to 40%.
A second series of meta-analyses were performed using 2-, 3-, and 4-year survival as endpoints. Figure 2 shows the results of the pooled analysis for 2-year overall survival. Chemoradiation produced a 20% improvement in 2-year survival versus radiation therapy alone, although the odds ratio of 0.80 was marginally non-statistically significant, i.e., 95% CI ϭ 0.63 to 1.02. The ORp for 3-year disease-free survival was of the same magnitude, i.e., 0.81 (95% CI ϭ 0.66 -1.00). The positive impact of combined chemoradiation persisted even at 4 years after treatment. Pooling all six studies using 4-year overall survival as the endpoint showed a 21% improvement over radiation therapy alone with a statistically significant CI of 0.65 to 0.97 (data not shown). Overall, the data suggest an approximate 20% improve-ment in 2-to 4-year survival with the addition of chemotherapy to standard external beam radiation therapy.
DISCUSSION
Radiation therapy is currently considered the standard therapeutic approach for the majority of patients with NPC. Despite the fact that high survival rates can be achieved with radiation therapy alone for early-stage lesions, control of advanced tumors remains poor. The anatomy of the nasopharynx makes local control problematic in that delivery of high-dose radiation is complicated by surrounding dose-limiting structures. Advanced neck disease is also associated with a high risk of distant metastases. Chemotherapy, whether neoadjuvant, adjuvant, or concomitant, has been added to the treatment regimen for NPC in numerous randomized and nonrandomized studies in an attempt to improve on the limited response associated with radiation therapy alone. Despite high response rates to chemotherapy, the impact of chemotherapy on disease-free and overall survival remains controversial. 14 Several agents are currently recognized as showing activity in NPC. These include methotrexate, bleomycin, doxorubicin, cisplatin, paclitaxel, and 5-fluorouracil. 15 Some evidence exists that multidrug regimens are superior to single agents, with cisplatin-based combinations being the most active. 16 Because of the continuing controversy regarding the integration of chemotherapy with standard radiation therapy in this disease, we conducted the present metaanalysis to provide a clearer understanding of the impact of combined-modality treatment on the natural history of regionally advanced NPC. Using disease-free and overall survival as the endpoints of interest, chemotherapy appeared to increase survival by approximately 20% to 40%. There was a clear, statistically significant increase in disease-free survival at 2, 3, and 4 years after treatment, whereas overall survival was improved by approximately 20% at 2 to 4 years after treatment.
As outlined in the text, the study by Al-Sarraf et al. 7 using concurrent cisplatin and radiation followed by postradiotherapy cisplatin and 5-fluorouracil showed the greatest improvement in disease-free/progression-free and overall survival versus adjuvant or neoadjuvant therapy. Unfortunately, this is the only currently available randomized trial using concurrent cisplatin-based chemotherapy. This fact precludes definitive conclusions regarding its true superiority to other regimens. A recent trial from Hong Kong using a similar approach also reported a trend toward improved 2-year progressionfree survival, although no overall survival advantage was seen with a median follow-up of approximately 2 years. 16 Because these data have only been presented in abstract form, they were not included in the present meta-analysis. Nonetheless, mature data from this trial may provide further support for concurrent chemoradiation in this setting.
Some additional, although limited, support for the above contention is seen via the study by Rossi et al. 12 included in the present meta-analysis. These investigators used postradiation vincristine, cyclophosphamide, and doxorubicin. No significant effect on progressionfree or overall survival was demonstrated. It is likely that this non-cisplatin-containing regimen is inferior to other protocols using cisplatin as cited above. Nonetheless, the Rossi et al. trial had other problems including relatively poor compliance with the chemotherapy regimen and exclusion of a large proportion of patients from the postradiotherapy chemotherapy study arm.
Despite the fact that the present analysis includes data on more than 1,500 patients, insufficient information exists regarding the optimal strategy for integrating chemotherapy with radiation in the treatment of NPC. Although cisplatin based regimens appear the most active, it is unclear what constitutes the best drug schedule and drug combination. Concurrent chemoradiation may be superior to neoadjuvant schedules, but this requires confirmation in additional randomized trials. In addition, radiation dose is an important consideration. It is currently possible to deliver greater than the standard 70 Gy to the primary site using permanent interstitial implants of iodine-125 or temporary high dose-rate intracavitary implants using iridium-192. Higher radiation doses may contribute substantially to improve local control and result in increased survivals. Future studies will need to address the possible impact of higher radiation doses to the primary tumor as well as address the associated toxicity of such treatment regimens.
In the absence of additional randomized trials addressing the above-cited issues, it appears reasonable to con-sider the Intergroup study 0099 regimen as a standard approach to patients with locally advanced NPC. The present meta-analysis provides support for this contention. Clearly, there is a need for further randomized clinical trials addressing the integration of chemotherapy and radiation in this disease setting. The combinedmodality regimen used by Al-Sarraf et al. may represent an acceptable "standard therapy" arm in future randomized trials.
